New combo therapy aims to improve glucose control in type 1 diabetes
NCT ID NCT07087795
First seen Apr 19, 2026 · Last updated May 14, 2026 · Updated 7 times
Summary
This early-stage study tests a new drug, NNC0194-0499, in 96 adults with type 1 diabetes. The goal is to see if adding this drug, alone or with semaglutide, helps keep blood sugar in a healthy range better than placebo. All participants continue their usual insulin. The study lasts about 36 weeks and focuses on safety and blood sugar control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS TYPE 1 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Profil Institut für Stoffwechselforschung GmbH
Neuss, 41460, Germany
Conditions
Explore the condition pages connected to this study.